Drug Trial Radar · NCT04009499
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,131
Actual
Start
Aug 13, 2019
Primary completion
May 26, 2026
Study completion May 26, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
Conditions
- Psoriatic Arthritis
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) during the studyTime frame: From PA0012 Entry Visit until Safety Follow-Up (up to Week 212)
- Incidence of treatment-emergent serious adverse events (SAEs) during the studyTime frame: From PA0012 Entry Visit until Safety Follow-Up (up to Week 212)
Locations
138 sites in 14 countries. Site status is shown where the registry gives one.
Pa0012 50017
Phoenix, Arizona
Pa0012 50035
San Diego, California
Pa0012 50033
Palm Harbor, Florida
Pa0012 50037
Tampa, Florida
Pa0012 50039
Atlanta, Georgia
Pa0012 50024
Boise, Idaho
Pa0012 50028
Lexington, Kentucky
Pa0012 50023
Baton Rouge, Louisiana
Pa0012 50015
Hagerstown, Maryland
Pa0012 50047
Boston, Massachusetts
Pa0012 50019
Lansing, Michigan
Pa0012 50016
St Louis, Missouri
Pa0012 50005
Freehold, New Jersey
Pa0012 50029
Albuquerque, New Mexico
Pa0012 50010
Brooklyn, New York
Pa0012 50011
New York, New York
Pa0012 50034
Rochester, New York
Pa0012 50125
Charlotte, North Carolina
Pa0012 50031
Winston-Salem, North Carolina
Pa0012 50040
Vandalia, Ohio
Pa0012 50020
Duncansville, Pennsylvania
Pa0012 50006
Wyomissing, Pennsylvania
Pa0012 50008
Johnston, Rhode Island
Pa0012 50007
Orangeburg, South Carolina
Pa0012 50001
Jackson, Tennessee
Pa0012 50012
Memphis, Tennessee
Pa0012 50002
Austin, Texas
Pa0012 50049
Corpus Christi, Texas
Pa0012 50036
Mesquite, Texas
Pa0012 50009
Waco, Texas
Pa0012 50050
Beckley, West Virginia
Pa0012 30005
Camberwell, Australia
Pa0012 30002
Clayton, Australia
Pa0012 30008
Hobart, Australia
Pa0012 30003
Maroochydore, Australia
Pa0012 30007
Victoria Park, Australia
Pa0012 30006
Woodville South, Australia
Pa0012 40003
Genk, Belgium
Pa0012 40002
Leuven, Belgium
Pa0012 40059
Mons, Belgium
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.